AbbVie (ABBV) Stock Price, News & Analysis

Company Overview

AbbVie Inc. (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott’s diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.

AbbVie’s immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions. Its neuroscience products include Botox Therapeutic, Vraylar, Ubrelvy and Qulipta, while its aesthetics business markets Botox Cosmetic and the Juvéderm collection of dermal fillers. AbbVie also develops and markets treatments in oncology, including Imbruvica, Venclexta and Epkinly, as well as products in eye care and women’s health.

The company sells its products in the United States and international markets through commercial operations, research activities and partnerships spanning numerous countries. AbbVie is headquartered in North Chicago, Illinois. Robert A. Michael has served as the company’s chief executive officer since 2020, following a leadership succession from longtime CEO Richard A. Gonzalez.

Key Stats

• Today's Range: $262.59 to $266.00
• 50-Day Range: $243.64 to $265.63
• 52-Week Range: $190.75 to $269.39
• Volume: 276,780 shs
• Average Volume: 6.48 million shs
• Market Capitalization: $466.56 billion
• P/E Ratio: 74.60
• Dividend Yield: 2.62%
• Price Target: $276.64
• Consensus Rating: Moderate Buy

AbbVie Stock Analysis - MarketRank™

AbbVie scored higher than 79% of companies evaluated by MarketBeat, and ranked 112th out of 908 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

AbbVie has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 2 strong buy ratings, 18 buy ratings, 5 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for AbbVie is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

AbbVie has been the subject of 18 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 14.95%

Earnings Growth

Earnings for AbbVie are expected to grow by 14.95% in the coming year, from $14.05 to $16.15 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AbbVie is 74.87, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.93.

Price to Earnings Ratio vs. Sector

The P/E ratio of AbbVie is 74.87, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.39.

Price to Earnings Growth Ratio

AbbVie has a PEG Ratio of 1.20. PEG Ratios above 1 indicate that a company could be overvalued.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.10% of the float of AbbVie has been sold short.

Short Interest Ratio / Days to Cover

AbbVie has a short interest ratio ("days to cover") of 4.48.

Change versus previous month

Short interest in AbbVie has recently decreased by 0.10%, indicating that investor sentiment is improving.

Dividend

• Score: 3.3 / 5
• Dividend Strength: Strong

Dividend Yield

AbbVie pays a meaningful dividend of 2.61%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

AbbVie has been increasing its dividend for 53 years.

Dividend Coverage

The dividend payout ratio of AbbVie is 195.48%. Payout ratios above 75% are not desirable because they may not be sustainable.

Dividend Sustainability

Based on earnings estimates, AbbVie will have a dividend payout ratio of 42.85% next year. This indicates that AbbVie will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.68

News Sentiment

AbbVie has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 37 news articles for AbbVie this week, compared to 10 articles on an average week.

Search Interest

Only 67 people have searched for ABBV on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

MarketBeat Follows

87 people have added AbbVie to their MarketBeat watchlist in the last 30 days. This is an increase of 45% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, AbbVie insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,177,500.00 in company stock.

Percentage Held by Insiders

0.06% of the stock of AbbVie is held by insiders.

Percentage Held by Institutions

70.23% of the stock of AbbVie is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Record date for 8/14 Dividend: 7/15/2026
• Ex-Dividend for 8/14 Dividend: 7/15/2026
• Last Earnings: 7/31/2026
• Dividend Payable: 8/14/2026
• Today: 9/25/2026
• Record date for 11/16 Dividend: 10/15/2026
• Ex-Dividend for 11/16 Dividend: 10/15/2026
• Next Earnings (Estimated): 10/30/2026
• Dividend Payable: 11/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSE:ABBV
• CIK: 1551152
• Web: www.abbvie.com
• Phone: (847) 932-7900
• Fax: 302-655-5049
• Employees: 57,000
• Year Founded: 2013

Price Target and Rating

• Average Price Target for AbbVie: $276.64
• High Price Target: $315.00
• Low Price Target: $223.00
• Potential Upside/Downside: +5.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.88
• Research Coverage: 25 Analysts

Profitability

• EPS (Trailing Twelve Months): $3.54
• Trailing P/E Ratio: 74.42
• Forward P/E Ratio: 18.75
• P/E Growth: 1.2
• Net Income: $4.23 billion
• Net Margins: 9.80%
• Pretax Margin: 13.51%
• Return on Equity: -422.07%
• Return on Assets: 14.34%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.81
• Quick Ratio: 0.69

Sales & Book Value

• Annual Sales: $61.16 billion
• Price / Sales: 7.61
• Cash Flow: $15.05 per share
• Price / Cash Flow: 17.51
• Book Value: ($1.83) per share
• Price / Book: -143.96

Miscellaneous

• Outstanding Shares: 1,766,790,000
• Free Float: 1,765,733,000
• Market Cap: $465.45 billion
• Optionable: Optionable
• Beta: 0.29